Merck boosts its full-year outlook as third-quarter earnings top estimates following strong demand for its blockbuster cancer ...

Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset ...

With vaccine sales on the decline, these are tough times for Merck to launch its new pneumococcal shot Capvaxive. | With ...

Q3 earnings beat estimates, but shares dip as 2025 sales outlook narrows. Get key highlights and pharma market insights.

More and more, as momentum builds for the soon-to-be-blockbuster Winrevair, Merck’s $11.5 billion buyout of Acceleron in 2021 is looking like a savvy move. | Paving the way for the label update were ...

Merck and Japan's Eisai said on Wednesday they will shut down a late-stage study testing an experimental combination therapy ...

Merck is breaking ground on a new 400,000-square-foot manufacturing facility in Elkton, Virginia, as part of its $70 billion ...

The combination of Merck's Welireg and Eisai's Lenvima has not yet shown statistical significance in extending overall ...

The company will begin its domestic investment by starting construction on a $3 billion pharmaceutical manufacturing site in ...

Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on ...

Pharmaceutical giant Merck & Co. is breaking ground on a $3 billion expansion of its longtime Elkton manufacturing campus, a ...

Merck, a leading science and technology company, has entered into a partnership with Promega Corporation, a global life ...